Swissmedic approved Coartem Baby, a malaria treatment for infants weighing between 2 and 5 kilograms. This is a significant milestone as it is only the third fast-track authorization for medicines targeted at helping developing nations combat malaria. The medication is a lower dosage combination of two antimalarials and allows for safe treatment of young children, which has been problematic with existing drugs meant for older children. Experts emphasize the importance of access to appropriate medications for all children, especially the very young and lightweight.
The newly approved medication, Coartem Baby, is a combination of two antimalarials designed specifically for infants weighing between 2 and 5 kilograms, marking a significant development in malaria treatment.
This approval represents only the third instance of a treatment being authorized under a fast-track process to facilitate access to essential medications for developing countries affected by malaria.
Collection
[
|
...
]